Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Precigen, Inc. (PGEN : NSDQ)
 
 • Company Description   
Precigen Inc. is a biopharmaceutical company. It specialise in the development of gene and cell therapies for immuno-oncology, autoimmune disorders and infectious diseases. The company's transformative therapeutic platforms, including UltraCAR-T(TM), AdenoVerse(TM) cytokine therapies, multifunctional therapeutics and off-the-shelf AdenoVerse(TM) immunotherapies, as well as ActoBio Therapeutics, Exemplar Genetics and Triple-Gene from our subsidiaries. Precigen Inc., formerly known as Intrexon Corporation, is based in Germantown, Maryland.

Number of Employees: 143

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.90 Daily Weekly Monthly
20 Day Moving Average: 4,547,839 shares
Shares Outstanding: 297.97 (millions)
Market Capitalization: $1,162.09 (millions)
Beta: 1.71
52 Week High: $5.23
52 Week Low: $0.65
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 25.00% 21.73%
12 Week 32.65% 27.15%
Year To Date 248.21% 204.37%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
20374 Seneca Meadows Parkway
-
Germantown,MD 20876
USA		 ph: 301-556-9900
fax: -		 investors@precigen.com http://www.precigen.com
 
 • General Corporate Information   
Officers
Helen Sabzevari - Chief Executive Officer
Randal J. Kirk - Executive Chairman
Harry Thomasian Jr. - Chief Financial Officer
Nancy H. Agee - Director
Cesar L. Alvarez - Director

Peer Information
Precigen, Inc. (CORR.)
Precigen, Inc. (RSPI)
Precigen, Inc. (CGXP)
Precigen, Inc. (BGEN)
Precigen, Inc. (GTBP)
Precigen, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 74017N105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/25
Next Expected EPS Date: 11/13/25
Share - Related Items
Shares Outstanding: 297.97
Most Recent Split Date: (:1)
Beta: 1.71
Market Capitalization: $1,162.09 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.03 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.28 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 11/13/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 267.76
EPS Growth
vs. Year Ago Period: -10.00%
vs. Previous Quarter: -57.14%
Sales Growth
vs. Year Ago Period: 19.39%
vs. Previous Quarter: -36.17%
ROE
09/30/25 - -
06/30/25 - -842.83
03/31/25 - -279.20
ROA
09/30/25 - -
06/30/25 - -78.98
03/31/25 - -79.74
Current Ratio
09/30/25 - -
06/30/25 - 2.71
03/31/25 - 3.53
Quick Ratio
09/30/25 - -
06/30/25 - 2.71
03/31/25 - 3.53
Operating Margin
09/30/25 - -
06/30/25 - -2,090.07
03/31/25 - -2,043.66
Net Margin
09/30/25 - -
06/30/25 - -2,868.66
03/31/25 - -3,728.87
Pre-Tax Margin
09/30/25 - -
06/30/25 - -2,870.32
03/31/25 - -3,770.86
Book Value
09/30/25 - -
06/30/25 - -0.12
03/31/25 - -0.05
Inventory Turnover
09/30/25 - -
06/30/25 - -
03/31/25 - -
Debt-to-Equity
09/30/25 - -
06/30/25 - -
03/31/25 - -
Debt-to-Capital
09/30/25 - -
06/30/25 - -
03/31/25 - 0.00
 

Powered by Zacks Investment Research ©